Sales & Marketing News | pharmaphorum

News

EU kicks off review of GSK's linerixibat in PBC

GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.

News

Madrigal closes on EU approval of first MASH treatment

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.

News

Grail plans FDA filing for cancer blood test after new trial

Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Could a Novo error set up early GLP-1 generics in Canada?

Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.

News

Gilead's twice-yearly PrEP drug is cleared by FDA

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

EU kicks off review of GSK's linerixibat in PBC

Madrigal closes on EU approval of first MASH treatment

Grail plans FDA filing for cancer blood test after new trial

Dupixent is first FDA-approved drug for rare skin disease

Could a Novo error set up early GLP-1 generics in Canada?

Gilead's twice-yearly PrEP drug is cleared by FDA

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks